News

SPP CLOSES OVERSUBSCRIBED

Adelaide, Australia: Bionomics Limited (ASX:BNO) today announced that its Share Purchase Plan (SPP) closed oversubscribed with $2,402,560 raised.

As previously announced, the amount to be raised under the SPP was capped at $2.2 million, underwritten by LINWAR Securities Pty Ltd. Accordingly subscribers of the issue will be scaled back on a pro rata basis based on the number of shares subscribed resulting in each subscriber receiving approximately 91.6% of their application.

Subject to the approval by shareholders of the issue of shares to Start-up Australia Ventures Pty Ltd at the EGM to be held this coming Friday 9 October, Bionomics will have successfully completed its $15 million capital raising.

Dr Peter Jonson, Chairman of Bionomics, commented "It is extremely gratifying to see the strong support shown by our loyal shareholders of this capital raising and, in particular, of the SPP. I am very pleased that approximately 15% of the capital raising was reserved for Bionomics' smaller shareholders and that we have been able to give them the opportunity to increase their holdings through the SPP. As a result of this capital raising, the Company is now very well placed to continue the development of its key programs in cancer and anxiety in an adequately funded manner and to execute its commercial strategy. As previously announced, in the absence of new opportunities or major developments, the directors have committed not to raise further equity capital for at least two years".

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited
Dr Deborah Rathjen
CEO & Managing Director
+618 8354 6101 / 0418 160 425
drathjen@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO) discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, epilepsy and multiple sclerosis. Bionomics' most advanced program, BNC105 for the treatment of cancer, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. Bionomics' discovery and development activities are driven by its three technology platforms: Angene®, the company's angiogenesis target and drug discovery platform, incorporates a variety of genomics tools to identify and validate novel angiogenesis targets. MultiCore® is Bionomics' proprietary, diversity orientated chemistry platform for the discovery of small molecule drugs. ionX® is a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system.

For more information about Bionomics, visit www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to the clinical evaluation of BNC105, our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Top